Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Pediatric Oncology

The Marathon: Treatment for High-Risk Neuroblastoma

At a Glance

Treatment for high-risk neuroblastoma is a 12-to-18-month process divided into three phases: induction to shrink the tumor, consolidation to eliminate microscopic cells, and maintenance to prevent recurrence. This aggressive approach includes chemotherapy, surgery, stem cell rescue, and immunotherapy.

Treating high-risk neuroblastoma is often described as a “marathon” because the process is intensive, involves multiple types of therapy, and typically lasts 12 to 18 months [1][2]. Because high-risk neuroblastoma is biologically aggressive and has a high risk of returning, doctors use an integrated, multimodal approach to attack the cancer from every possible angle [3][4].

Before this marathon begins, your team will likely discuss fertility preservation (such as freezing ovarian or testicular tissue) [5]. The treatments ahead are intense, and taking proactive steps early can protect your child’s future options.

The treatment is divided into three distinct phases: Induction, Consolidation, and Maintenance.

Phase 1: Induction (The Initial Attack)

The goal of the induction phase is to rapidly reduce the amount of cancer in the body and clear it from distant sites like the bone marrow [6][3].

  • Chemotherapy: Your child will receive several cycles of intensive chemotherapy. This “shrinks” the primary tumor and prepares it for removal [6][7].
  • Stem Cell Collection: Early in this phase, healthy blood-forming stem cells are collected from your child’s blood and frozen for later use [8][9].
  • Surgery: Once the chemotherapy has done its work, surgeons aim to remove as much of the primary tumor as safely possible [10][11].

Phase 2: Consolidation (The Deep Clean)

This phase aims to eliminate any “microscopic” cancer cells that might have survived the first round of treatment [1].

  • High-Dose Chemotherapy: Your child receives extremely strong chemotherapy designed to kill any remaining cancer. This dose is so high that it also destroys the healthy bone marrow [12][13].
  • Autologous Stem Cell Rescue (Transplant): When parents hear “transplant,” they often panic about finding a bone marrow match. However, this is an autologous transplant—meaning your child’s own healthy stem cells (collected during Induction) are infused back into their body [8][9]. You do not need to find a donor match. These cells “rescue” the body by growing new, healthy bone marrow. Many protocols now use a “tandem” (two) transplant approach to further improve outcomes [1][14].
  • Radiation Therapy: Targeted radiation is directed at the original site of the tumor to prevent it from growing back locally [15][16].

Phase 3: Maintenance (The Safety Net)

Even when scans show no visible cancer, tiny amounts of minimal residual disease (MRD) may remain [17]. Maintenance therapy is designed to hunt down and destroy these last few cells.

  • Immunotherapy (Dinutuximab): This is a specialized antibody that attaches to a marker called GD2 on the surface of neuroblastoma cells [17][18]. It acts like a “beacon,” telling your child’s own immune system to attack the cancer [19][20].
  • Cytokines & Evolving Protocols: Medicines like GM-CSF are often given alongside immunotherapy to boost the immune system [18][20]. However, protocols are constantly evolving, and clinical trials are continually testing whether these additions are strictly necessary.
  • Isotretinoin (Retinoid): This is a form of Vitamin A that helps any remaining immature cancer cells “mature” into normal cells that are less likely to grow back [17][21].

While this marathon is physically and emotionally demanding for the entire family, this aggressive, multi-step approach has significantly improved the chances of long-term survival for children with high-risk disease [22][23].

Return to the Home Page.

Common questions in this guide

How long does treatment for high-risk neuroblastoma take?
Treatment for high-risk neuroblastoma is an intensive process that typically lasts 12 to 18 months. Because the disease is aggressive, doctors use a multimodal approach that is divided into three distinct phases: induction, consolidation, and maintenance.
Should we consider fertility preservation before treatment begins?
Yes, because the treatments for high-risk neuroblastoma are intense, it is highly recommended to discuss options like freezing ovarian or testicular tissue before beginning therapy. Taking these proactive steps early can protect your child's future options.
Do we need to find a bone marrow match for a stem cell transplant?
No, you typically do not need to find a bone marrow donor match. Treatment protocols usually involve an autologous transplant, which means your child's own healthy stem cells are collected early in treatment and later infused back into their body to rescue the bone marrow.
What is the purpose of the maintenance phase?
Even when scans show no visible cancer, microscopic amounts of disease may remain. The maintenance phase uses targeted treatments, such as immunotherapy and retinoids, to hunt down and destroy these last few surviving cells to help prevent the cancer from returning.
What is Dinutuximab and how does it work?
Dinutuximab is a specialized immunotherapy antibody that targets a marker called GD2 found on the surface of neuroblastoma cells. It acts like a beacon, signaling your child's own immune system to recognize and attack the remaining cancer cells.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cycles of induction chemotherapy are planned before the primary tumor surgery?
  2. 2.Will my child receive a single autologous stem cell transplant or a 'tandem' (double) transplant?
  3. 3.Before induction begins, what are our options for fertility preservation (like ovarian or testicular tissue freezing)?
  4. 4.What specific pain management protocols are used during the immunotherapy cycles?
  5. 5.Are there long-term side effects of the high-dose chemotherapy that we should be monitoring for as my child grows?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Treatment of High-Risk Neuroblastoma.

    Krystal J, Foster JH

    Children (Basel, Switzerland) 2023; (10(8)) doi:10.3390/children10081302.

    PMID: 37628301
  2. 2

    Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects.

    Makimoto A, Fujisaki H, Matsumoto K, et al.

    Cancers 2024; (16(3)) doi:10.3390/cancers16030544.

    PMID: 38339295
  3. 3

    High-Risk Neuroblastoma Treatment Review.

    Smith V, Foster J

    Children (Basel, Switzerland) 2018; (5(9)) doi:10.3390/children5090114.

    PMID: 30154341
  4. 4

    Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations.

    Jain R, Hans R, Totadri S, et al.

    Pediatric blood & cancer 2020; (67(6)):e28273 doi:10.1002/pbc.28273.

    PMID: 32196923
  5. 5

    Musculoskeletal outcomes and the effect of radiation to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma.

    Ferris MJ, Tian S, Switchenko JM, et al.

    Journal of radiation oncology 2018; (7(2)):187-193 doi:10.1007/s13566-018-0349-4.

    PMID: 34178250
  6. 6

    Prognostic Value of a Semi-Quantitative Score Based on 123I-MIBG SPECT/CT in Pediatric Patients With Stage 4 High-Risk Neuroblastoma After Induction Therapy.

    Wang X, Wang G, Zhou Z, et al.

    Clinical nuclear medicine 2026; doi:10.1097/RLU.0000000000006372.

    PMID: 41729085
  7. 7

    Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

    Park JR, Kreissman SG, London WB, et al.

    JAMA 2019; (322(8)):746-755 doi:10.1001/jama.2019.11642.

    PMID: 31454045
  8. 8

    Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients.

    Dalla Palma B, Accardi F, Prezioso L, et al.

    Leukemia & lymphoma 2020; (61(5)):1238-1241 doi:10.1080/10428194.2019.1706735.

    PMID: 31905295
  9. 9

    Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma.

    Zirngibl F, Flemmig C, Lang P, et al.

    Children (Basel, Switzerland) 2020; (7(11)) doi:10.3390/children7110198.

    PMID: 33126407
  10. 10

    Emergency Surgical Management of Chemotherapy-Induced Tumor Rupture in a Patient with MYCN-Amplified Neuroblastoma: A Case Report.

    Ogawa K, Makita S, Utsunomiya A, et al.

    Surgical case reports 2025; (11(1)) doi:10.70352/scrj.cr.25-0473.

    PMID: 41235320
  11. 11

    The pre-surgical factors that determine the decision to proceed to resection in children diagnosed with high-risk neuroblastoma in a resource limited setting.

    van Heerden J, Kruger M, Esterhuizen TM, et al.

    Pediatric hematology and oncology 2023; (40(3)):242-257 doi:10.1080/08880018.2022.2137610.

    PMID: 36271813
  12. 12

    Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).

    Jung SH, Lee JJ, Kim JS, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; (24(5)):923-929 doi:10.1016/j.bbmt.2018.01.004.

    PMID: 29339269
  13. 13

    Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.

    Bashir Q, Thall PF, Milton DR, et al.

    The Lancet. Haematology 2019; (6(5)):e266-e275 doi:10.1016/S2352-3026(19)30023-7.

    PMID: 30910541
  14. 14

    Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand.

    Suwannaying K, Techavichit P, Komvilaisak P, et al.

    Clinical and experimental pediatrics 2022; (65(9)):453-458 doi:10.3345/cep.2022.00437.

    PMID: 35619231
  15. 15

    Role and toxicity of radiation therapy in neuroblastoma patients: A literature review.

    Zhao Q, Liu Y, Zhang Y, et al.

    Critical reviews in oncology/hematology 2020; (149()):102924 doi:10.1016/j.critrevonc.2020.102924.

    PMID: 32172225
  16. 16

    Local control and toxicity outcomes following consolidative radiation therapy in patients with high-risk neuroblastoma: a 20-year experience at a single center.

    Jang JY, Park JH, Kim YJ, et al.

    The Turkish journal of pediatrics 2024; (66(1)):99-109.

    PMID: 38523384
  17. 17

    Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.

    Ploessl C, Pan A, Maples KT, Lowe DK

    The Annals of pharmacotherapy 2016; (50(5)):416-22 doi:10.1177/1060028016632013.

    PMID: 26917818
  18. 18

    Cytokine-induced killer cells/natural killer cells combined with anti-GD2 monoclonal antibody increase cell death rate in neuroblastoma SK-N-SH cells.

    Zhang C, Xiong X, Li Y, et al.

    Oncology letters 2019; (18(6)):6525-6535 doi:10.3892/ol.2019.11020.

    PMID: 31807172
  19. 19

    Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

    Siebert N, Troschke-Meurer S, Marx M, et al.

    Cancers 2018; (10(10)) doi:10.3390/cancers10100387.

    PMID: 30336605
  20. 20

    Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO.

    Siebert N, Zumpe M, von Lojewski L, et al.

    Oncoimmunology 2020; (9(1)):1836768 doi:10.1080/2162402X.2020.1836768.

    PMID: 33150046
  21. 21

    Dinutuximab: A Review in High-Risk Neuroblastoma.

    Hoy SM

    Targeted oncology 2016; (11(2)):247-53 doi:10.1007/s11523-016-0420-2.

    PMID: 26891967
  22. 22

    Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

    Yu AL, Gilman AL, Ozkaynak MF, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(8)):2179-2189 doi:10.1158/1078-0432.CCR-20-3909.

    PMID: 33504555
  23. 23

    Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.

    Mora J

    Expert review of clinical pharmacology 2016; (9(5)):647-53 doi:10.1586/17512433.2016.1160775.

    PMID: 26934530

This page provides an overview of high-risk neuroblastoma treatment phases for educational purposes. Always consult your child's pediatric oncology team to understand their specific treatment protocol and options.

Get notified when new evidence is published on Neuroblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.